Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: An overview of recent phase II studies

Medical Science Monitor

Volumn 8, Issue 6, 2002, Pages

  Kosmas, Christos ^a   Tsavaris, Nicolas ^a   Kalofonos, Haralambos P ^a  

^a HELENA VENIZELOU HOSPITAL   (Greece)

Author keywords

NSCLC; Paclitaxel; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDICAL LITERATURE; MUCOSA INFLAMMATION; PEER REVIEW; PHASE 2 CLINICAL TRIAL; PUBLICATION; SALVAGE THERAPY;

EID: 0036283808     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
2. Gemcirabine and docetaxel as second-line chemotherapy non-small cell lung cancer failing prior paclitaxel plus platinum-based regimens
3. Second-line chemotherapy for non-small-ceil lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
4. A phase II study of paditaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer
5. Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin combination chemotherapy in advanced solid tumors
6. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
7. Phase II trial of weekly doceraxel in second-line therapy for nonsmall cell lung carcinoma
8. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma
9. A phase 11 study of docetaxel ill patients with paclitaxel-resistant breast cancer
10. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer
11. Salvage therapy with gemcitabine in advanced non-small cell lung cancer progressing after prior carboplatin-paclitaxel
12. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase 11 trial
13. Activity of gemcitabine in cisplatin-pretreated patients with advanced non-small cell lung cancer: A phase II trial
14. Gemcitabine in platinun treated non-small cell lung cancer
15. Phase 11 study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer
16. Activity ofdocetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
17. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere
18. Bcl2 is the guardian of microtubule intergrity
19. Taxotere is an active drug in non small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG)
20. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
21. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
22. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial
23. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
24. Docetaxel (Taxotere) plus cisplatin: An active and well-tolerated combination in patients with advanced need non-small cell lung cancer
25. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
26. Randomized phase Ill trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
27. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell carcinoma. A Minnie Pearl Cancer Research Network phase II trial
28. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based reghnens
29. Failure of vinorelbine to produce responses in pretreated non-small-cell lung cancer
30. Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer
31. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome
32. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
33. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase 11 trial
34. A novel administration of gemcitabine (via constant dose rate) in combination with docetaxel in advanced non-small cell lung cancer
35. A phase II study of docetaxel and gemcitabine combination in patients with non-small cell lung cancer
36. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial